earticle

논문검색

세프질® 정 250밀리그람 (세프프로질 250밀리그람)에 대한 프로세질 정 250밀리그람의 생물학적동등성

원문정보

Bioequivalence of Procezil Tablet 250 mg to Cefzil® Tablet 250 mg (Cefprozil 250 mg)

김세미, 강민선, 조혜영, 이용복

피인용수 : 0(자료제공 : 네이버학술정보)

초록

영어

Cefprozil is a broad-spectrum oral beta-lactam cephalosporin consisting of cis- and trans-isomeric mixture whose ratio is approximately 90:10. Cefprozil is used to treat certain infections caused by bacteria such as bronchitis and ear, skin, and throat infections. The purpose of the present study was to evaluate the bioequivalence of two cefprozil tablets, Cefzil® tablet 250 mg (BMS Pharmaceutical Korea., Ltd.) and Procezil tablet 250 mg (Hanmi Pharm. Co., Ltd.), according to the guidelines of the Korea Food and Drug Administration (KFDA). The in vitro release of cefprozil from the two cefprozil formulations were tested using KP VIII Apparatus I method with water dissolution media. Thirty five healthy male subjects, 24.00±1.53 years in age and 69.77±9.99 kg in body weight, were divided into two groups and a randomized 2×2 cross-over study was employed. After four tablets containing 1000 mg as cefprozil were orally administered, blood samples were taken at predetermined time intervals and the concentrations of cefprozil in serum were determined using HPLC/UV detector. The dissolution profiles of two formulations were similar in water tested dissolution media. The pharmacokinetic parameters such as AUCt, Cmax and Tmax on the basis of total-cefprozil were calculated, and computer program (K-BE Test 2002) was utilized for the statistical analysis of the parameters using
logarithmically transformed AUCt, Cmax and untransformed Tmax. The results showed that the differences between two formulations based on the reference drug, Cefzil® tablets, were -0.81%, -3.00% and -6.83% for AUCt, Cmax and Tmax, respectively. There were no sequence effects between two formulations in these parameters. The 90% confidence intervals using logarithmically transformed data were within the acceptance range of log 0.8 to log 1.25 (e.g., log 0.9515~log 1.0454 and log 0.9613~log 1.0465 for AUCt and Cmax, respectively). Thus, the criteria of the KFDA bioequivalence guideline were satisfied, indicating Procezil tablet was bioequivalent to Cefzil® tablet.

목차

Abstract
 실험방법
  시약 및 기기
  비교용출시험
  피험자 선정
  약물 투약 및 혈액 채취
  혈청 중 세프프로질의 정량
  약물속도론적 파라미터의 분석
 결과 및 고찰
  비교용출시험
  혈청 중 세프프로질 정량
  혈청 중 세프프로질 농도 추이
  평가항목에 대한 통계학적 고찰
 결론
 참고문헌

저자정보

  • 김세미 Se-Mi Kim. 종근당 종합연구소
  • 강민선 Min-Sun Kang. 전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소
  • 조혜영 Hea-Young Cho. 식품의약품안전청 임상제도과
  • 이용복 Yong-Bok Lee. 전남대학교 약학대학 부속 생물학적동등성 및 가교시험연구소

참고문헌

자료제공 : 네이버학술정보

    함께 이용한 논문

      ※ 기관로그인 시 무료 이용이 가능합니다.

      • 4,000원

      0개의 논문이 장바구니에 담겼습니다.